The 2026 Healthtech Messaging Index
Imvaria
imvaria.com·scored August 23, 2026
13/38
Weak
The signal is faint. Most of this page is about Imvaria, not the buyer, and AI has little it can repeat. There's a lot of room to move.
The page we scored
The AI Recommendation Check
When we asked AI who to recommend for AI-powered medical diagnostic software for interstitial lung disease and pulmonary fibrosis, it named:
Buyer we put in the prompt: Pulmonologist or radiology department head at a US hospital or health system evaluating AI diagnostic tools for interstitial lung disease. Both the buyer and the category were inferred from Imvaria’s homepage alone. The model had no web access.
Imvaria was not on the list.
A buyer who asked AI this question got 8 names and moved on. Imvaria never came up.
We asked AI who it recommends for "Pulmonologist or radiology department head at a US hospital or health system evaluating AI diagnostic tools for interstitial lung disease" looking for "AI-powered medical diagnostic software for interstitial lung disease and pulmonary fibrosis". It named Imbio, VIDA Diagnostics, Intelerad, Optellum, Coreline Soft. You did not appear. AI can't recommend what it can't clearly understand.
Overall assessment
IMVARIA's biggest strength is its demonstrated, specific authority ... FDA De Novo authorization, Breakthrough Device Designation, AMA CPT code adoption, and a Mayo Clinic collaboration make it objectively distinguishable and credible. The biggest gap is that the homepage is effectively a press release archive with zero conversion architecture: no hero, no ICP statement, no CTA, no buyer journey, and no problem-first narrative ... a pulmonologist landing here has no path to take action and no immediate reason to care.
Signal by category
Narrative Clarity
8 signals
Trust Signal
4 signals
AI Signal
6 signals
Conversion Signal
1 signal
Weakest signal · fix this first
01The 7-Second Test
“The scraped content is entirely press releases ... no hero section, headline, or above-the-fold narrative visible.”
A stranger landing on this page sees a press release announcement, not a clear statement of who this is for, what problem it solves, or any point of view ... fails the 7-second test completely.
All 19 signals, scored 0 to 2.
Total 13/38
Narrative Clarity
8 signals
- 0
01The 7-Second Testweakest
“The scraped content is entirely press releases ... no hero section, headline, or above-the-fold narrative visible.”
A stranger landing on this page sees a press release announcement, not a clear statement of who this is for, what problem it solves, or any point of view ... fails the 7-second test completely.
- 0
02Rebellion / Movement
“No named enemy, status quo critique, or industry pattern being pushed against anywhere on the page.”
The page never names what's broken about current lung disease diagnosis beyond passive references to 'diagnostic delays' ... there is no rebellion or movement framing.
- 1
03Owned Language & Category
“'Digital Biomarker Lab' and 'software-as-medical-device (SaMD) company pioneering AI-driven digital biomarker solutions'”
The term 'digital biomarker' is used consistently and product names Fibresolve and ScreenDx are coined, but no owned category frame or named methodology is declared that AI could cite as distinctly IMVARIA's.
- 1
04ICP Clarity
“'thousands of pulmonologists who treat patients with lung diseases'”
Pulmonologists are mentioned but only in passing quotes ... no explicit ICP statement by role, institution type, or patient volume appears anywhere on the page.
- 0
05Problem Leadership
“No problem-first framing exists; the page opens with 'IMVARIA Announces Presentations at American Thoracic Society International Conference'”
Every section leads with company news and achievements, never with the buyer's problem stated in the buyer's language before the solution.
- 1
06Solution Clarity
“'AI-driven digital biomarker solutions that empower clinicians to make accurate diagnoses and prognoses at earlier stages of disease'”
A visitor could roughly summarize what IMVARIA does, but only after reading the boilerplate 'About' section buried below press releases ... the hero does not deliver this clarity.
- 0
07Cost of Inaction
“No mention of consequences of delayed adoption, lost revenue, or cost of inaction for the clinician or health system buyer.”
The page never names what a pulmonologist or health system loses by not adopting IMVARIA's tools ... stakes are entirely absent from the narrative.
- 0
08Promised Land
“No 'after state' description for the clinician or health system buyer exists on the page.”
Patient outcome language appears ('better-informed decisions') but no specific promised land ... a transformed workflow, reduced diagnosis time, or revenue outcome ... is painted for the buyer.
Trust Signal
4 signals
- 1
09Proof & Evidence
“'nearly two-and-a-half-year delay in the diagnosis from the initial manifestation of symptoms' and 'over 125,000 deaths have occurred due lung cancer'”
Disease-level statistics are present but there are no before/after deltas, customer outcome numbers, or product-specific performance metrics cited.
- 1
10Social Proof
“'Joshua Mooney, MD, MS, Clinical Assistant Professor, Medicine ... Pulmonary, Allergy & Critical Care at Stanford Medicine'”
One named clinician quote exists and Mayo Clinic is named as a partner, but there are no customer logos, multiple testimonials, or case study evidence from paying customers.
- 2
11Authority & Credibility
“'Founded in 2019 by physician-engineers from Google and Stanford University' and 'FDA De Novo Marketing Authorization' and 'FDA Breakthrough-Designated AI diagnostic tool'”
FDA authorization, Breakthrough Device Designation, AMA CPT code adoption, Mayo Clinic collaboration, and Google/Stanford founder credentials constitute demonstrated, specific authority.
- 0
12Alternatives Acknowledged
“No mention of competing diagnostic approaches, competitor products, or 'do nothing' alternative anywhere on the page.”
The page never acknowledges what clinicians are currently doing instead of using IMVARIA ... invasive biopsy is mentioned but not framed as the explicit alternative being displaced.
AI Signal
6 signals
- 0
13Customer Focus
“Page opens: 'IMVARIA Announces Presentations at American Thoracic Society International Conference Featuring IMVARIA's AI-Driven Digital Biomarker Technology'”
Every section is told from the company's perspective ... announcements, milestones, and authorizations ... with the customer/clinician appearing only as a beneficiary, not as protagonist.
- 1
14AI-Parmesan Index
“'machine-learning algorithm technology to transform clinical decision-making into data science' and 'AI-trained algorithm to provide non-invasive adjunct information'”
AI claims go somewhat beyond generic 'AI-powered' language by naming CT imaging analysis and pattern recognition, but mechanism specificity is thin and the phrase 'AI-driven' is repeated generically throughout.
- 1
15LLM Quotability
“'the first ever FDA authorization of a diagnostic tool of any type in lung fibrosis, and the first FDA Breakthrough-Designated AI diagnostic tool with simultaneously adopted CPT billing codes'”
This sentence is highly quotable and citation-ready, but it is buried in a press release rather than structured as a clean declarative positioning statement on a proper homepage.
- 2
16Copyright Freshness
“'Berkeley, Calif. ... May 18, 2025' and 'Berkeley, Calif. ... January 13, 2025'”
The page contains dated press releases through May 2025, providing clear recency signals that AI engines can use to assess freshness.
- 2
17Entity Distinctiveness
“'first ever FDA-authorized AI adjunctive diagnostic service of any type in lung fibrosis' with named products Fibresolve and ScreenDx and CPT billing codes”
The combination of FDA-first status, named products, lung fibrosis specificity, and CPT billing code integration makes IMVARIA distinguishable from generic AI diagnostics competitors ... an AI could only attribute this description to them.
- 0
18AI Recommendation Check
“AI's picks: Imbio, VIDA Diagnostics, Intelerad, Optellum, Coreline Soft, Siemens Healthineers AI-Rad Companion. You were not named.”
We asked AI who it recommends for "Pulmonologist or radiology department head at a US hospital or health system evaluating AI diagnostic tools for interstitial lung disease" looking for "AI-powered medical diagnostic software for interstitial lung disease and pulmonary fibrosis". It named Imbio, VIDA Diagnostics, Intelerad, Optellum, Coreline Soft. You did not appear. AI can't recommend what it can't clearly understand.
Conversion Signal
1 signal
- 0
19Path & CTA Clarity
“No CTA buttons, no numbered process steps, no 'book a demo' or 'learn more' path visible anywhere in the scraped content.”
The entire page is press releases with no primary CTA, no secondary CTA, and no visible buyer journey or process ... conversion architecture is completely absent.
Your move
Think Imvaria’s score is wrong? Good. Let’s look at it together.
Twenty minutes with Greg. Bring the page, bring the argument. You’ll leave knowing exactly which signal is costing Imvaria the AI recommendation, and what to write instead.
Not on the list? Run your homepage through the free Brand Signal Score and see where you’d land. Same 19 signals, same AI check, two minutes.